Drug class profile · refreshed daily from federal data

Serotonin and Norepinephrine Reuptake Inhibitor

1 molecule in this class, $104.4M combined CY2024 Part D spend across 1.5M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Serotonin and Norepinephrine Reuptake Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class
1tracked in Part D
CY24 Part D spend
$104.4Mcombined across class
Total Rx claims
1.5M356K unique beneficiaries
Generic mfrs (active)
9across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard
01
Desvenlafaxine
Brand: Desvenlafaxine · 1.5M Part D claims (CY24) · 356K beneficiaries · First FDA approval:
9 generic mfrs 2 plans require PA
Low NADAC$0.420
Avg plan cost$2.50
Part D spend $104.4M spread, current vs floor
Class share
100%
of class CY24 spend
View profile →